Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Pathologic Complete Response × Neoadjuvant Therapy × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 3 Triple Negative Breast Neoplasms 1 Rectal Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Multiple Myeloma 1 Microsatellite Instability 1 Melanoma 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 High-Risk Cancer 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Intraductal, Noninfiltrating 1

Interventions

pembrolizumab 2 durvalumab 2 Standard of Care 2 Paclitaxel 2 Oxaliplatin 2 Irinotecan 2 Chemoradiotherapy 2 Carboplatin 2 Capecitabine 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 talazoparib 1 sarilumab 1 relugolix 1 regorafenib 1 pexidartinib 1 pertuzumab 1 patritumab 1 olaparib 1 niraparib 1 neratinib 1 ganitumab 1 enzalutamide 1 dostarlimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡